In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 11.62 below Structure Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 36 other companies have achieved higher Quick Ratio than Structure Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 101 to 218.

Explain Quick Ratio?
How much Cash & cash equivalents GPCR�s has?
What are GPCR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GPCR/financial-strength

https://api.csimarket.com/api/v1/companies/GPCR/fundamentals

https://api.csimarket.com/api/v1/companies/GPCR/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

GPCR Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	86.18 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	55.77 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	11.62	Subscribe	Subscribe	Subscribe	Subscribe
GPCR's Total Ranking	# 218	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	62 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-7.3 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 37
Healthcare Sector	# 56
Overall Market	# 218

Quick Ratio Statistics
High	Average	Low
53.95	26.45	9.24
(Jun 30 2025)		(Dec 31 2022)

Financial Statements
Structure Therapeutics Inc 's Current Liabilities	$ 107 Millions	Visit GPCR's Balance sheet
Structure Therapeutics Inc 's Cash & cash equivalent	$ 1,245 Millions	Visit GPCR's Balance sheet
Source of GPCR's Sales		Visit GPCR's Sales by Geography

Cumulative Structure Therapeutics Inc 's Quick Ratio

GPCR's Quick Ratio for the trailling 12 Months

GPCR Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	102.94 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	66.13 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	18.71	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 151	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	20.33 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	8.83 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to GPCR Financial Strength Comparisons >> Go to Compare GPCR Quick Ratio to its Competitors

News about Structure Therapeutics Inc Quick Ratio

Structure Therapeutics Inc. Raises $547.4 Million in Public Offering, Faces Quick Ratio Challenges

Structure Therapeutics Inc. recently announced the successful closing of its upsized underwritten public offering, which saw the sale of 10,427,017 American depositary shares (ADSs) at a price of $52.50 per ADS. This resulted in aggregate gross proceeds of approximately $547.4 million for the company.
However, despite a sequential decrease in current liabilities, the company s Quick Ratio deteriorated to 18.5 in the first quarter of 2024, below the industry average of 27.15. In comparison to other companies within the industry, Structure Therapeutics Inc. now ranks lower than it did in the previous quarter, at 100.
Looking at the trailing twelve months basis, the decrease in current liabilities led to a cumulative Quick Ratio of 18, still above the industry average. However, when compared to other companies in the industry, Structure Therapeutics Inc. falls behind with only 231 outperforming companies in terms of Quick Ratio.
While the company has seen an improvement in its overall ranking for Quick Ratio over the past twelve months, the recent figures suggest there is room for improvement. It will be interesting to see how Structure Therapeutics Inc. utilizes the proceeds from the public offering to strengthen its financial position and potentially improve its Quick Ratio in the future

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2026 to $107.10 millions, cumulative Quick Ratio decreased to 18.71 above the GPCR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 414 other companies have achieved higher Quick Ratio than Structure Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2138 to 3219.

Explain Quick Ratio?
How much Cash & cash equivalents GPCR�s has?
What are GPCR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 415
Healthcare Sector	# 846
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
10.5	7.63	3.82
(Jun 30 2026)		(Mar 31 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Immix Biopharma Inc	30.89	$ 336.303 Millions	$ 10.889 Millions
Minerva Neurosciences Inc	30.46	$ 76.945 Millions	$ 2.526 Millions
Contineum Therapeutics Inc	30.45	$ 244.484 Millions	$ 8.028 Millions
Latigo Biotherapeutics, Inc.	28.73	$ 401.241 Millions	$ 13.964 Millions
Amylyx Pharmaceuticals Inc	26.44	$ 768.132 Millions	$ 29.048 Millions
Climb Bio Inc	25.98	$ 205.423 Millions	$ 7.906 Millions
Prothena Corporation Public Limited Company	23.73	$ 271.368 Millions	$ 11.434 Millions
Innoviva Inc	22.67	$ 1,134.297 Millions	$ 50.030 Millions
Kailera Therapeutics Inc	21.40	$ 901.454 Millions	$ 42.116 Millions
Cryoport inc	20.47	$ 653.343 Millions	$ 31.911 Millions
Roivant Sciences Ltd	20.30	$ 5,683.045 Millions	$ 279.911 Millions
Disc Medicine Inc	19.87	$ 682.816 Millions	$ 34.360 Millions
Relmada Therapeutics Inc	19.30	$ 202.123 Millions	$ 10.474 Millions
Mbx Biosciences Inc	19.14	$ 481.594 Millions	$ 25.167 Millions
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Equillium Inc	18.92	$ 53.322 Millions	$ 2.819 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions
Alto Neuroscience Inc	17.90	$ 319.344 Millions	$ 17.836 Millions
Upstream Bio Inc	17.34	$ 207.365 Millions	$ 11.960 Millions
Siga Technologies Inc	17.27	$ 116.380 Millions	$ 6.738 Millions
Arrivent Biopharma inc	16.86	$ 393.691 Millions	$ 23.357 Millions
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Whitehawk Therapeutics Inc	16.25	$ 169.672 Millions	$ 10.441 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Sellas Life Sciences Group Inc	14.51	$ 134.711 Millions	$ 9.286 Millions
Protagonist Therapeutics inc	14.42	$ 800.064 Millions	$ 55.464 Millions

Date modified: 2026-11-11T13:45:08+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.